glp-1 patch clinical trial Patches': Do the Products Influencers Are Selling Work? In the gray world of

The single published human case series and unpublished clinical trial data provide preliminary safety reassurance but insufficient evidence for clinical efficacy claims

doi: 10.1530/EJE-07-0271 36 FeolaTCozzolinoASimonelliISbardellaEPozzaCGianettaEet al

Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with alcohol use disorder (AUD) and either type 2 diabetes or obesity who started a newer GLP-1 RA (semaglutide, tirzepatide) to similar individuals starting alternative medications

maintenance: lower doses 23 times per week)

How this acquisition helps close that gap: Broader disease coverage addressing both early and advanced stages of MASH

A stronger skin barrier means better moisture retention, reduced sensitivity, and improved protection against environmental stressors that accelerate the aging process